Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease

Journal of Neuroimmunology

Volumn 137, Issue 1-2, 2003, Pages 32-41

  Quinn, Joseph ^a,b   Montine, Thomas ^c   Morrow, Jason ^d   Woodward, William R ^b   Kulhanek, Doris ^b   Eckenstein, Felix ^e  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

Alzheimer; Animal model; Cyclooxygenase; F2 isoprostanes; Indomethacin; Nonsteroidal anti inflammatory drug; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; INDOMETACIN; PROSTAGLANDIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DISEASE; BRAIN INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HORMONE DETERMINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

EID: 0037376760     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00037-7     Document Type: Article

References (45)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol. 126:2002;50-57.
2. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., Weiner M.F., Farlow M.R., Sano M., Grundman M., Thal L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 54:2000;588-593.
3. Aisen P., Schafer K., Grundman M., Farlow M., Sano S., Jin S., Thomas R., Thal L. Results of a multicenter trial of rofecoxib and naproxen in Alzheimer's disease. Neurobiol. Aging. 23(1S):2002;S429.
4. Akiyama H., Arai T., Kondo H., Tanno E., Haga C., Ikeda K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc. Disord. 14:2000;S47-S53.
5. Apelt J., Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 894:2001;21-30.
6. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., Brunden K.R. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging. 20:1999;581-589.
7. DiCarlo G., Wilcock D., Henderson D., Gordon M., Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging. 22:2001;1007-1012.
8. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152:1998;307-317.
9. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
10. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 33:1998;883-889.
11. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
12. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., Gordon M.N. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22:2002;2246-2254.
13. Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 16:2002;601-603.
14. Kruman I.I., Kumaravel T.S., Lohani A., Pedersen W.A., Cutler R.G., Kruman Y., Haughey N., Lee J., Evans M., Mattson M.P. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J. Neurosci. 22:2002;1752-1762.
15. Lala P.K., Al-Mutter N., Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int. J. Cancer. 73:1997;371-380.
16. Landolfi C., Soldo L., Polenzani L., Apicella C., Capezzone de Joannon A., Coletta I., Di Cesare F., Brufani M., Pinza M., Milanese C. Inflammatory molecule release by beta-amyloid-treated T98G astrocytoma cells: role of prostaglandins and modulation by paracetamol. Eur. J. Pharmacol. 360:1998;55-64.
17. Lee R.K., Knapp S., Wurtman R.J. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J. Neurosci. 19:1999;940-947.
18. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:2000;5709-5714.
19. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21:2001;8370-8377.
20. Lim G.P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., Overmier J.B., Hsiao-Ashec K., Frautschy S.A., Cole G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging. 22:2001;983-991.
21. Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9:1999;133-146.
22. McGeer E.G., McGeer P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharm. Des. 5:1999;821-836.
23. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
24. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 374:1995;647-650.
25. Mehlhorn G., Hollborn M., Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18:2000;423-431.
26. Montine K.S., Montine T.M., Morrow J.D., Frei B., Milatovic D., Eckenstein F., Quinn J.F. Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment. Brain Res. 930:2002;75-82.
27. Morrow J.D., Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1997;1-21.
28. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. II A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9383-9387.
29. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152:1998;871-877.
30. Prasad K.N., Hovland A.R., La Rosa F.G., Hovland P.G. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc. Soc. Exp. Biol. Med. 219:1998;120-125.
31. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21:2001;4183-4187.
32. Qiao X., Cummins D.J., Paul S.M. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci. 14:2001;474-482.
33. Quinn J., Davis F., Woodward W.R., Eckenstein F. Beta-amyloid plaques induce neuritic dystrophy of nitric oxide-producing neurons in a transgenic mouse model of Alzheimer's disease. Exp. Neurol. 168:2001;203-212.
34. Sainati S.et al. Results of a double-blind, placebo-controlled study of Celebrex for the progression of Alzheimer's disease. Proceedings of the 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy. Stockholm, Sweden. 2002;180.
35. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
36. Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley D.D., Carter D.B., Chin J.E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 56:2001;581-588.
37. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:1998;2212-2215.
38. Stalder M., Deller T., Staufenbiel M., Jucker M. 3D-reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging. 22:2001;427-434.
39. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2:2000;379-385.
40. Tehranian R., Hasanvan H., Iverfeldt K., Post C., Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci. Lett. 301:2001;54-58.
41. Van Gool W.A., Weinstein H.C., Scheltens P.K., Walstra G.J. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 358:2001;455-460.
42. Watkins L.R., Hansen M.K., Nguyen K.T., Lee J.E., Maier S.F. Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Life Sci. 65:1999;449-481.
43. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
44. Wegiel J., Wang K.C., Imaki H., Rubenstein R., Wronska A., Osuchowski M., Lipinski W.J., Walker L.C., LeVine H. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol. Aging. 22:2001;49-61.
45. Yan Q., Zhang J., Liu H., Babu-Khan S., Citron M.O., Landreth G.E. Anti-inflammatory drug therapy alters beta amyloid processing and deposition in an animal model of Alzheimer's disease. Soc. Neurosci. Abstr. 2002;483-485. (Abstract).